KCM
BHVN

Kingdon Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Kingdon Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-136,306
Closed -$16.2M – 105
2022
Q1 		$16.2M Sell
136,306
-164,067
-55% -$20.5M 1.68% 17
2021
Q4 		$41.4M Sell
300,373
-65,000
-18% -$8.27M 4.76% 4
2021
Q3 		$50.8M Sell
365,373
-35,633
-9% -$4.45M 6.17% 3
2021
Q2 		$38.9M Sell
401,006
-459,255
-53% -$37.3M 4.51% 5
2021
Q1 		$58.8M Sell
860,261
-370,000
-30% -$29.9M 6.01% 4
2020
Q4 		$105M Sell
1,230,261
-80,000
-6% -$6.78M 11.41% 1
2020
Q3 		$85.2M Buy
1,310,261
+8,000
+0.6% +$524K 9.56% 1
2020
Q2 		$95.2M Sell
1,302,261
-160,500
-11% -$8.54M 8.66% 4
2020
Q1 		$49.8M Buy
1,462,761
+205,041
+16% +$9.38M 9.11% 1
2019
Q4 		$68.5M Buy
1,257,720
+100,946
+9% +$5M 10.31% 1
2019
Q3 		$48.3M Buy
1,156,774
+155,364
+16% +$6.56M 5.7% 2
2019
Q2 		$43.9M Buy
1,001,410
+157,144
+19% +$8.86M 4.31% 3
2019
Q1 		$43.5M Buy
844,266
+173,528
+26% +$7.5M 5.81% 1
2018
Q4 		$24.8M Buy
670,738
+48,410
+8% +$1.75M 3.74% 8
2018
Q3 		$23.4M Buy
622,328
+24,732
+4% +$910K 1.63% 18
2018
Q2 		$23.6M Buy
597,596
+81,859
+16% +$2.6M 1.65% 16
2018
Q1 		$13.3M Buy
+515,737
New +$15.4M 1.05% 31

Other funds holding BHVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kingdon Capital Management's BHVN Position: Q2 2022 in Review

Kingdon Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 136,306 shares — an estimated $16.2M sold.

Kingdon Capital Management first reported a position in BHVN in Q1 2018 and held it in 17 quarters. The position peaked at $105M in Q4 2020. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

  • Kingdon Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
  • Kingdon Capital Management sold 136,306 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $16.2M.
  • Kingdon Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018 and held it in 17 quarters.
  • Kingdon Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $105M in Q4 2020.
  • 329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Kingdon Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.